文献速递其他结缔组织病

抑制转谷氨酰胺酶2改善人三维全层皮肤的纤维化重塑

Amelioration of Fibrotic Remodeling of Human 3-Dimensional Full-Thickness Skin by Transglutamase 2 Inhibition.
PubMed 文献 · Arthritis Rheumatol · 2023-07-05

研究评估转谷氨酰胺酶2(TG2)在系统性硬化症(SSc)成纤维细胞活化中的作用,并利用单克隆抑制性抗TG2抗体在二维和三维全层皮肤模型中测试其抗纤维化效果。结果显示SSc患者皮肤及成纤维细胞中TG2表达和活性增加,抗TG2抗体在三维模型中有效减轻TGF-β诱导的真皮增厚、肌成纤维细胞分化和胶原沉积,提示抑制TG2可能是SSc的潜在抗纤维化策略。

要点

  • SSc患者皮肤TG2表达较健康对照增高,SSc相关间质性肺病患者中尤其高。
  • SSc患者血浆循环TG2水平较健康对照增高。
  • 抗TG2抗体在三维全层皮肤模型中减轻TGF-β诱导的真皮增厚、肌成纤维细胞分化和胶原沉积。

核心结论

  • 研究首次提供证据表明抑制TG2可能是SSc的潜在抗纤维化方法。
  • 抗TG2抗体目前正在慢性同种异体移植物损伤的II期临床试验中评估,因此可用于SSc的临床研究(ClinicalTrials.gov标识符:NCT04335578)。

研究设计与样本

  • 研究评估TG2表达和活性采用TG2染色、蛋白质印迹和TG2活性测定。
  • 在标准二维培养的成纤维细胞和三维全层等效皮肤模型中,使用单克隆抑制性抗TG2抗体抑制TG2。

主要发现

  • SSc患者皮肤中TG2表达较健康对照增高,SSc相关间质性肺病患者中水平尤其高。
  • SSc真皮成纤维细胞中TG2表达和TG2活性增加。
  • SSc患者血浆样本中循环TG2水平较健康对照样本增高。
  • 在二维培养条件下,抗TG2抗体在不同成纤维细胞系间未显示一致的抗纤维化效果。
  • 在三维全层人皮肤模型中,抗TG2抗体有效减少转化生长因子β诱导的真皮增厚、肌成纤维细胞分化和胶原积累。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Fibrotic tissues are characterized by excessive crosslinking between extracellular matrix (ECM) proteins, rendering them more resistant to degradation. Although increased crosslinking of ECM is thought to play an important role for progression of tissue fibrosis, enhanced ECM crosslinking has not yet been targeted therapeutically in systemic sclerosis (SSc). Here, we investigated the role of transglutaminase 2 (TG2), a central crosslinking enzyme, in the activation of SSc fibroblasts. METHODS: We assessed TG2 expression and activity using TG2 staining, Western blotting, and TG2 activity assays. We inhibited TG2 in fibroblasts cultured under standard 2-dimensional conditions and in a 3-dimensional full-thickness equivalent skin model using monoclonal inhibitory anti-TG2 antibodies. RESULTS: TG2 expression was increased in the skin of patients with SSc compared with healthy controls, with levels particularly high in patients with SSc-associated interstitial lung disease. TG2 expression and TG2 activity were also increased in SSc dermal fibroblasts. Moreover, the levels of circulating TG2 in the plasma samples from SSc patients were increased versus samples from healthy controls. Anti-TG2 antibodies did not show consistent antifibrotic effects across different fibroblast cell lines under 2-dimensional culture conditions; however, anti-TG2 antibodies effectively reduced transforming growth factor β-induced dermal thickening, myofibroblast differentiation, and collagen accumulation in the 3-dimensional full-thickness model of human skin. CONCLUSION: We provide the first evidence, to our knowledge, that inhibition of TG2 might be a potential antifibrotic approach in SSc. Our findings have translational potential as anti-TG2 antibodies are currently evaluated in a phase II clinical trial in chronic allograft injury and would thus be available for clinical studies in SSc (ClinicalTrials.gov identifier: NCT04335578).

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Zhou X, Trinh-Minh T, Matei AE, et al. Amelioration of Fibrotic Remodeling of Human 3-Dimensional Full-Thickness Skin by Transglutamase 2 Inhibition. Arthritis Rheumatol. 2023. PMID: 37057394. doi:10.1002/art.42518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。